{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T06:47:05Z","timestamp":1784616425233,"version":"3.55.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,4]],"date-time":"2022-07-04T00:00:00Z","timestamp":1656892800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,4]],"date-time":"2022-07-04T00:00:00Z","timestamp":1656892800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100005468","name":"Batten Disease Support and Research Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005468","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["NS R21 106523"],"award-info":[{"award-number":["NS R21 106523"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P50 HD103525"],"award-info":[{"award-number":["P50 HD103525"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["NS R21 106523"],"award-info":[{"award-number":["NS R21 106523"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000268","name":"Biotechnology and Biological Sciences Research Council","doi-asserted-by":"publisher","award":["BBS\/E\/D\/10002071"],"award-info":[{"award-number":["BBS\/E\/D\/10002071"]}],"id":[{"id":"10.13039\/501100000268","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Cannabidiol (CBD) has gained attention as a therapeutic agent and is purported to have immunomodulatory, neuroprotective, and anti-seizure effects. Here, we determined the effects of chronic CBD administration in a mouse model of CLN1 disease (\n                    <jats:italic>Cln1<\/jats:italic>\n                    <jats:sup>\u2212\/\u2212<\/jats:sup>\n                    ) that simultaneously exhibits neuroinflammation, neurodegeneration, and spontaneous seizures. Proteomic analysis showed that putative CBD receptors are expressed at similar levels in the brains of\n                    <jats:italic>Cln1<\/jats:italic>\n                    <jats:sup>\u2212\/\u2212<\/jats:sup>\n                    mice compared to normal animals.\n                    <jats:italic>Cln1<\/jats:italic>\n                    <jats:sup>\u2212\/\u2212<\/jats:sup>\n                    mice received an oral dose (100\u00a0mg\/kg\/day) of CBD for six months and were evaluated for changes in pathological markers of disease and seizures. Chronic cannabidiol administration was well-tolerated, high levels of CBD were detected in the brain, and markers of astrocytosis and microgliosis were reduced. However, CBD had no apparent effect on seizure frequency or neuron survival. These data are consistent with CBD having immunomodulatory effects. It is possible that a higher dose of CBD could also reduce neurodegeneration and seizure frequency.\n                  <\/jats:p>","DOI":"10.1038\/s41598-022-15134-5","type":"journal-article","created":{"date-parts":[[2022,7,4]],"date-time":"2022-07-04T11:03:01Z","timestamp":1656932581000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Effects of chronic cannabidiol in a mouse model of naturally occurring neuroinflammation, neurodegeneration, and spontaneous seizures"],"prefix":"10.1038","volume":"12","author":[{"given":"Joshua T.","family":"Dearborn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hemanth R.","family":"Nelvagal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas R.","family":"Rensing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keigo","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie M.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.","family":"Wishart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan D.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S.","family":"Sands","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,4]]},"reference":[{"key":"15134_CR1","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.phrs.2016.01.033","volume":"112","author":"AC Campos","year":"2016","unstructured":"Campos, A. C., Fogaca, M. V., Sonego, A. B. & Guimaraes, F. S. Cannabidiol, neuroprotection and neuropsychiatric disorders. Pharmacol. Res. 112, 119\u2013127 (2016).","journal-title":"Pharmacol. Res."},{"key":"15134_CR2","first-page":"277","volume":"41","author":"JP Szaflarski","year":"2014","unstructured":"Szaflarski, J. P. & Bebin, E. M. Cannabis, cannabidiol, and epilepsy\u2013from receptors to clinical response. E&B 41, 277\u2013282 (2014).","journal-title":"E&B"},{"key":"15134_CR3","unstructured":"Devinsky, O. et al. Efficacy and safety of Epidiolex (cannabidiol) in children and young adults with treatment-resistant epilepsy: Update from the Expanded Access Program. in (2015)."},{"key":"15134_CR4","unstructured":"Cross, J. H. et al. Cannabidiol (CBD) significantly reduces convulsive seizure frequency in Dravet Syndrome (DS): Results of a multi-center, randomized, double-blind, placebo-controlled trial (GWPCARE1). in (2016)."},{"key":"15134_CR5","unstructured":"Thiele, E. et al. Cannabidiol (CBD) significantly reduces drop seizure seizure frequency in Lennox-Gastaut Syndrome (LGS): Results of a multi-center, randomized, double-blind, placebo-controlled trial (GWPCARE4). in (2016)."},{"key":"15134_CR6","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1001\/jamaneurol.2020.4607","volume":"78","author":"EA Thiele","year":"2021","unstructured":"Thiele, E. A. et al. Add-on cannabidiol treatment for drug-resistant seizures in tuberous sclerosis complex: A placebo-controlled randomized clinical trial. JAMA Neurol. 78, 285\u2013292 (2021).","journal-title":"JAMA Neurol."},{"key":"15134_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fnbeh.2020.612624","volume":"14","author":"G Cabral-Pereira","year":"2021","unstructured":"Cabral-Pereira, G. et al. Behavioral and molecular effects induced by cannabidiol and valproate administration in the GASH\/Sal model of acute audiogenic seizures. Front. Behav. Neurosci. 14, 612624 (2021).","journal-title":"Front. Behav. Neurosci."},{"key":"15134_CR8","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.1111\/epi.16973","volume":"62","author":"MS Fallah","year":"2021","unstructured":"Fallah, M. S., Dlugosz, L., Scott, B. W., Thompson, M. D. & Burnham, W. M. Antiseizure effects of the cannabinoids in the amygdala-kindling model. Epilepsia 62, 2274\u20132282 (2021).","journal-title":"Epilepsia"},{"key":"15134_CR9","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.seizure.2021.04.008","volume":"90","author":"CL Fr\u00edas-Soria","year":"2021","unstructured":"Fr\u00edas-Soria, C. L., P\u00e9rez-P\u00e9rez, D., Orozco-Su\u00e1rez, S. & Rocha, L. Cannabidiol modifies the seizure expression and effects of antiseizure drugs in a rat model of recurrent severe seizures. Seizure 90, 67\u201373 (2021).","journal-title":"Seizure"},{"key":"15134_CR10","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1124\/jpet.109.159145","volume":"332","author":"NA Jones","year":"2010","unstructured":"Jones, N. A. et al. Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo. J. Pharmacol. Exp. Ther. 332, 569\u2013577 (2010).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"15134_CR11","doi-asserted-by":"publisher","first-page":"11229","DOI":"10.1073\/pnas.1711351114","volume":"114","author":"JS Kaplan","year":"2017","unstructured":"Kaplan, J. S., Stella, N., Catterall, W. A. & Westenbroek, R. E. Cannabidiol attenuates seizures and social deficits in a mouse model of Dravet syndrome. PNAS 114, 11229\u201311234 (2017).","journal-title":"PNAS"},{"key":"15134_CR12","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1016\/j.bbadis.2013.04.008","volume":"1832","author":"A Schulz","year":"2013","unstructured":"Schulz, A., Kohlsch\u00fctter, A., Mink, J., Simonati, A. & Williams, R. NCL diseases\u2014clinical perspectives. Biochim. Biophys. Acta 1832, 1801\u20131806 (2013).","journal-title":"Biochim. Biophys. Acta"},{"key":"15134_CR13","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1177\/0883073813493665","volume":"28","author":"S-B Dolisca","year":"2013","unstructured":"Dolisca, S.-B., Mehta, M., Pearce, D. A., Mink, J. W. & Maria, B. L. Batten disease: Clinical aspects, molecular mechanisms, translational science, and future directions. J. Child Neurol. 28, 1074\u20131100 (2013).","journal-title":"J. Child Neurol."},{"key":"15134_CR14","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1038\/376584a0","volume":"376","author":"J Vesa","year":"1995","unstructured":"Vesa, J. et al. Mutations in the palmitoyl protein thioesterase gene causing infantile neuronal ceroid lipofuscinosis. Nature 376, 584\u2013587 (1995).","journal-title":"Nature"},{"key":"15134_CR15","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1111\/j.1469-8749.1974.tb04183.x","volume":"16","author":"P Santavuori","year":"1974","unstructured":"Santavuori, P., Haltia, M. & Rapola, J. Infantile type of so-called neuronal ceroid-lipofuscinosis. Dev. Med. Child Neurol. 16, 644\u2013653 (1974).","journal-title":"Dev. Med. Child Neurol."},{"key":"15134_CR16","unstructured":"Frazier, M. Batten disease parent survey (2017)."},{"key":"15134_CR17","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s00213-011-2415-0","volume":"219","author":"S Deiana","year":"2012","unstructured":"Deiana, S. et al. Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), \u03949-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive\u2013compulsive behaviour. Psychopharmacology 219, 859\u2013873 (2012).","journal-title":"Psychopharmacology"},{"key":"15134_CR18","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s13311-015-0377-3","volume":"12","author":"C Ibeas Bih","year":"2015","unstructured":"Ibeas Bih, C. et al. Molecular targets of cannabidiol in neurological disorders. Neurotherapeutics 12, 699\u2013730 (2015).","journal-title":"Neurotherapeutics"},{"key":"15134_CR19","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.3389\/fphar.2020.595635","volume":"11","author":"F Patricio","year":"2020","unstructured":"Patricio, F., Morales-Andrade, A. A., Patricio-Mart\u00ednez, A. & Lim\u00f3n, I. D. Cannabidiol as a therapeutic target: Evidence of its neuroprotective and neuromodulatory function in Parkinson\u2019s disease. Front. Pharmacol. 11, 2092 (2020).","journal-title":"Front. Pharmacol."},{"key":"15134_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.etap.2019.103202","volume":"70","author":"C Xu","year":"2019","unstructured":"Xu, C. et al. Pharmacokinetics of oral and intravenous cannabidiol and its antidepressant-like effects in chronic mild stress mouse model. Environ. Toxicol. Pharmacol. 70, 103202 (2019).","journal-title":"Environ. Toxicol. Pharmacol."},{"key":"15134_CR21","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1111\/epi.12631","volume":"55","author":"O Devinsky","year":"2014","unstructured":"Devinsky, O. et al. Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia 55, 791\u2013802 (2014).","journal-title":"Epilepsia"},{"key":"15134_CR22","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.nbd.2006.09.001","volume":"25","author":"C Kielar","year":"2007","unstructured":"Kielar, C. et al. Successive neuron loss in the thalamus and cortex in a mouse model of infantile neuronal ceroid lipofuscinosis. Neurobiol. Dis. 25, 150\u2013162 (2007).","journal-title":"Neurobiol. Dis."},{"key":"15134_CR23","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1111\/nan.12658","volume":"47","author":"HR Nelvagal","year":"2021","unstructured":"Nelvagal, H. R., Dearborn, J. T., Ostergaard, J. R., Sands, M. S. & Cooper, J. D. Spinal manifestations of CLN1 disease start during the early postnatal period. Neuropathol. Appl. Neurobiol. 47, 251\u2013267 (2021).","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"15134_CR24","doi-asserted-by":"publisher","first-page":"15575","DOI":"10.1523\/JNEUROSCI.3579-11.2011","volume":"31","author":"SL Macauley","year":"2011","unstructured":"Macauley, S. L., Pekny, M. & Sands, M. S. The role of attenuated astrocyte activation in infantile neuronal ceroid lipofuscinosis. J. Neurosci. 31, 15575\u201315585 (2011).","journal-title":"J. Neurosci."},{"key":"15134_CR25","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s40478-018-0575-4","volume":"6","author":"J Lange","year":"2018","unstructured":"Lange, J. et al. Compromised astrocyte function and survival negatively impact neurons in infantile neuronal ceroid lipofuscinosis. Acta Neuropathol. Commun. 6, 74 (2018).","journal-title":"Acta Neuropathol. Commun."},{"key":"15134_CR26","doi-asserted-by":"publisher","first-page":"13077","DOI":"10.1523\/JNEUROSCI.2518-14.2014","volume":"34","author":"SL Macauley","year":"2014","unstructured":"Macauley, S. L. et al. An anti-neuroinflammatory that targets dysregulated glia enhances the efficacy of CNS-directed gene therapy in murine infantile neuronal ceroid lipofuscinosis. J. Neurosci. 34, 13077\u201313082 (2014).","journal-title":"J. Neurosci."},{"key":"15134_CR27","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.nbd.2004.03.005","volume":"16","author":"M Griffey","year":"2004","unstructured":"Griffey, M. et al. Adeno-associated virus 2-mediated gene therapy decreases autofluorescent storage material and increases brain mass in a murine model of infantile neuronal ceroid lipofuscinosis. Neurobiol. Dis. 16, 360\u2013369 (2004).","journal-title":"Neurobiol. Dis."},{"key":"15134_CR28","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1002\/ana.23545","volume":"71","author":"SL Macauley","year":"2012","unstructured":"Macauley, S. L. et al. Synergistic effects of central nervous system-directed gene therapy and bone marrow transplantation in the murine model of infantile neuronal ceroid lipofuscinosis. Ann. Neurol. 71, 797\u2013804 (2012).","journal-title":"Ann. Neurol."},{"key":"15134_CR29","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.ymthe.2005.11.008","volume":"13","author":"MA Griffey","year":"2006","unstructured":"Griffey, M. A. et al. CNS-directed AAV2-mediated gene therapy ameliorates functional deficits in a murine model of infantile neuronal ceroid lipofuscinosis. Mol. Ther. 13, 538\u2013547 (2006).","journal-title":"Mol. Ther."},{"key":"15134_CR30","doi-asserted-by":"publisher","first-page":"13566","DOI":"10.1073\/pnas.251485198","volume":"98","author":"P Gupta","year":"2001","unstructured":"Gupta, P. et al. Disruption of PPT1 or PPT2 causes neuronal ceroid lipofuscinosis in knockout mice. Proc. Natl. Acad. Sci. USA 98, 13566\u201313571 (2001).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"15134_CR31","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.nbd.2004.02.010","volume":"16","author":"E Bible","year":"2004","unstructured":"Bible, E., Gupta, P., Hofmann, S. L. & Cooper, J. D. Regional and cellular neuropathology in the palmitoyl protein thioesterase-1 null mutant mouse model of infantile neuronal ceroid lipofuscinosis. Neurobiol. Dis. 16, 346\u2013359 (2004).","journal-title":"Neurobiol. Dis."},{"key":"15134_CR32","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1177\/0883073813494479","volume":"28","author":"TG K\u00fchl","year":"2013","unstructured":"K\u00fchl, T. G., Dihanich, S., Wong, A. M. S. & Cooper, J. D. Regional brain atrophy in mouse models of neuronal ceroid lipofuscinosis: A new rostrocaudal perspective. J. Child Neurol. 28, 1117\u20131122 (2013).","journal-title":"J. Child Neurol."},{"key":"15134_CR33","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s10545-011-9421-6","volume":"35","author":"J Cialone","year":"2012","unstructured":"Cialone, J. et al. Females experience a more severe disease course in batten disease. J. Inherit. Metab. Dis. 35, 549\u2013555 (2012).","journal-title":"J. Inherit. Metab. Dis."},{"key":"15134_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.pneurobio.2020.101789","volume":"189","author":"TB Johnson","year":"2020","unstructured":"Johnson, T. B. et al. A multimodal approach to identify clinically relevant biomarkers to comprehensively monitor disease progression in a mouse model of pediatric neurodegenerative disease. Prog. Neurobiol. 189, 101789 (2020).","journal-title":"Prog. Neurobiol."},{"key":"15134_CR35","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13023-019-0994-8","volume":"14","author":"MJ Poppens","year":"2019","unstructured":"Poppens, M. J. et al. Tracking sex-dependent differences in a mouse model of CLN6-Batten disease. Orphanet J. Rare Dis. 14, 19 (2019).","journal-title":"Orphanet J. Rare Dis."},{"key":"15134_CR36","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.seizure.2020.09.010","volume":"86","author":"CGS Gilmartin","year":"2021","unstructured":"Gilmartin, C. G. S., Dowd, Z., Parker, A. P. J. & Harijan, P. Interaction of cannabidiol with other antiseizure medications: A narrative review. Seizure 86, 189\u2013196 (2021).","journal-title":"Seizure"},{"key":"15134_CR37","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1007\/BF02244012","volume":"100","author":"FS Guimar\u00e3es","year":"1990","unstructured":"Guimar\u00e3es, F. S., Chiaretti, T. M., Graeff, F. G. & Zuardi, A. W. Antianxiety effect of cannabidiol in the elevated plus-maze. Psychopharmacology 100, 558\u2013559 (1990).","journal-title":"Psychopharmacology"},{"key":"15134_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2021.108712","volume":"197","author":"GK Silva-Cardoso","year":"2021","unstructured":"Silva-Cardoso, G. K. et al. Cannabidiol effectively reverses mechanical and thermal allodynia, hyperalgesia, and anxious behaviors in a neuropathic pain model: Possible role of CB1 and TRPV1 receptors. Neuropharmacology 197, 108712 (2021).","journal-title":"Neuropharmacology"},{"key":"15134_CR39","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1007\/s00210-004-0871-3","volume":"369","author":"B Costa","year":"2004","unstructured":"Costa, B. et al. Oral anti-inflammatory activity of cannabidiol, a non-psychoactive constituent of cannabis, in acute carrageenan-induced inflammation in the rat paw. Naunyn-Schmiedeberg\u2019s Arch. Pharmacol. 369, 294\u2013299 (2004).","journal-title":"Naunyn-Schmiedeberg\u2019s Arch. Pharmacol."},{"key":"15134_CR40","doi-asserted-by":"crossref","unstructured":"Do Val-da Silva, R. A. et al. Protective effects of cannabidiol against seizures and neuronal death in a rat model of mesial temporal lobe epilepsy. Front. Pharmacol. 8, (2017).","DOI":"10.3389\/fphar.2017.00131"},{"key":"15134_CR41","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/0014-2999(82)90264-3","volume":"83","author":"P Consroe","year":"1982","unstructured":"Consroe, P., Benedito, M. A. C., Leite, J. R., Carlini, E. A. & Mechoulam, R. Effects of cannabidiol on behavioral seizures caused by convulsant drugs or current in mice. Eur. J. Pharmacol. 83, 293\u2013298 (1982).","journal-title":"Eur. J. Pharmacol."},{"key":"15134_CR42","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/j.1476-5381.1980.tb14562.x","volume":"68","author":"R Karler","year":"1980","unstructured":"Karler, R. & Turkanis, S. A. Subacute cannabinoid treatment: Anticonvulsant activity and withdrawal excitability in mice. Br. J. Pharmacol. 68, 479\u2013484 (1980).","journal-title":"Br. J. Pharmacol."},{"key":"15134_CR43","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.ymthe.2005.04.018","volume":"12","author":"M Griffey","year":"2005","unstructured":"Griffey, M., Macauley, S. L., Ogilvie, J. M. & Sands, M. S. AAV2-mediated ocular gene therapy for infantile neuronal ceroid lipofuscinosis. Mol. Therapy 12, 413\u2013421 (2005).","journal-title":"Mol. Therapy"},{"key":"15134_CR44","doi-asserted-by":"publisher","first-page":"e3000411","DOI":"10.1371\/journal.pbio.3000411","volume":"18","author":"NP du Sert","year":"2020","unstructured":"du Sert, N. P. et al. Reporting animal research: Explanation and elaboration for the ARRIVE guidelines 20. PLOS Biol. 18, e3000411 (2020).","journal-title":"PLOS Biol."},{"key":"15134_CR45","doi-asserted-by":"publisher","first-page":"15157","DOI":"10.1038\/s41598-020-72075-7","volume":"10","author":"HR Nelvagal","year":"2020","unstructured":"Nelvagal, H. R. et al. Comparative proteomic profiling reveals mechanisms for early spinal cord vulnerability in CLN1 disease. Sci. Rep. 10, 15157 (2020).","journal-title":"Sci. Rep."},{"key":"15134_CR46","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.neulet.2014.03.013","volume":"566","author":"AJ Hill","year":"2014","unstructured":"Hill, A. J. et al. Voltage-gated sodium (Nav) channel blockade by plant cannabinoids does not confer anticonvulsant effects per se. Neurosci. Lett. 566, 269\u2013274 (2014).","journal-title":"Neurosci. Lett."},{"key":"15134_CR47","volume-title":"The Mouse Brain in Stereotaxic Coordinates: Deluxe","author":"G Paxinos","year":"2001","unstructured":"Paxinos, G. & Franklin, K. B. J. The Mouse Brain in Stereotaxic Coordinates: Deluxe 2nd edn. (Academic Press, 2001).","edition":"2"},{"issue":"4","key":"15134_CR48","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1002\/ar.1092310411","volume":"231","author":"MJ West","year":"1991","unstructured":"West, M. J., Slomianka, L. & Gundersen, H. J. Unbiased stereological estimation of the total number of neurons in thesubdivisions of the rat hippocampus using the optical fractionator. Anat Rec. 231(4), 482\u2013497. https:\/\/doi.org\/10.1002\/ar.1092310411 (1991).","journal-title":"Anat Rec."},{"key":"15134_CR49","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/978-1-61779-430-8_24","volume":"821","author":"NR Rensing","year":"2012","unstructured":"Rensing, N. R., Guo, D. & Wong, M. Video-EEG monitoring methods for characterizing rodent models of tuberous sclerosis and epilepsy. Methods Mol. Biol. 821, 373\u2013391 (2012).","journal-title":"Methods Mol. Biol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-15134-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-15134-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-15134-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T01:10:58Z","timestamp":1669338658000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-15134-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,4]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["15134"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-15134-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.03.07.483344","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,4]]},"assertion":[{"value":"10 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Thomas Wishart is an academic editor at <i>Scientific Reports.<\/i> All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11286"}}